Generic Nayzilam Availability
Last updated on Apr 10, 2025.
Nayzilam is a brand name of midazolam, approved by the FDA in the following formulation(s):
NAYZILAM (midazolam - spray;nasal)
Is there a generic version of Nayzilam available?
No. There is currently no therapeutically equivalent version of Nayzilam available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Nayzilam. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Methods and compositions for the delivery of a therapeutic agent
Patent 8,217,033
Issued: July 10, 2012
Inventor(s): Gizurarson; Sveinbjorn
Assignee(s): Hananja EHF (Reyjavik, IS); University of Iceland (Reykjavik, IS)The present invention provides a liquid pharmaceutical composition comprising a therapeutic agent and an alkoxy-polyethylene glycol, for example, methoxy-polyethylene glycol, for administration of the therapeutic agent to the mammal. The compositions can be applied to a membrane, for example, a nasal membrane during intranasal administration. The invention also provides methods of administering such compositions to a mammal.
Patent expiration dates:
- January 18, 2028✓✓
- January 18, 2028
-
Methods and compositions for the delivery of a therapeutic agent
Patent 8,809,322
Issued: August 19, 2014
Inventor(s): Gizurarson; Sveinbjorn
Assignee(s): Hananja EHF (Reykjavik, IS); University of Iceland (Reykjavik, IS)The present invention provides a liquid pharmaceutical composition comprising a therapeutic agent and an alkoxy-polyethylene glycol, for example, methoxy-polyethylene glycol, for administration of the therapeutic agent to the mammal. The compositions can be applied to a membrane, for example, a nasal membrane during intranasal administration. The invention also provides methods of administering such compositions to a mammal.
Patent expiration dates:
- January 18, 2028✓
- January 18, 2028
-
Methods and compositions for the delivery of a therapeutic agent
Patent 9,289,432
Issued: March 22, 2016
Inventor(s): Gizurarson Sveinbjorn
Assignee(s): HANANJA EHF and UNIVERSITY OF ICELANDThe present invention provides a liquid pharmaceutical composition comprising a therapeutic agent and an alkoxy-polyethylene glycol, for example, methoxy-polyethylene glycol, for administration of the therapeutic agent to the mammal. The compositions can be applied to a membrane, for example, a nasal membrane during intranasal administration. The invention also provides methods of administering such compositions to a mammal.
Patent expiration dates:
- January 18, 2028✓✓
- January 18, 2028
-
Methods and systems for the delivery of a therapeutic agent
Patent 9,687,495
Issued: June 27, 2017
Inventor(s): Gizurarson; Sveinbjorn
Assignee(s): HANANJA EHF (Reykjavik, IS); UNIVERSITY OF ICELAND (Reykjavik, IS)The present invention provides a liquid pharmaceutical composition comprising a therapeutic agent and an alkoxy-polyethylene glycol, for example, methoxy-polyethylene glycol, for administration of the therapeutic agent to the mammal. The compositions can be applied to a membrane, for example, a nasal membrane during intranasal administration. The invention also provides methods of administering such compositions to a mammal.
Patent expiration dates:
- January 18, 2028✓✓
- January 18, 2028
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- May 17, 2026 - ACUTE TREATMENT OF INTERMITTENT, STEREOTYPIC EPISODES OF FREQUENT SEIZURE ACTIVITY (I.E., SEIZURE CLUSTERS, ACUTE REPETITIVE SEIZURES) THAT ARE DISTINCT FROM A PATIENT'S USUAL SEIZURE PATTERN IN PATIENTS WITH EPILEPSY 12 YEARS OF AGE AND OLDER
More about Nayzilam (midazolam)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (7)
- Drug images
- Latest FDA alerts (4)
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: benzodiazepines
- Breastfeeding
- En español
Patient resources
Other brands
Professional resources
Other brands
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
